Case of Severe Neutropenia Resolved by Suspension of Sitagliptin Intake in a Patient Also Treated with Metformin
Journal: International Research Journal of Pharmacy and Medical Sciences (IRJPMS) (Vol.6, No. 6)Publication Date: 2023-11-15
Authors : Cristallo Attilio F.; Paola Dimitri; Rebuttato Anna M.; Lanza Lorella; Mazzei Clemente F.;
Page : 18-20
Keywords : ;
Abstract
Neutropenia is a disorder characterized by a reduction in the absolute number of circulating neutrophils below age- and raceidentified normal limits. Sitagliptin is an oral antihyperglycemic agent licensed for the treatment of type 2 diabetes. The clinical case reviewed
in this report involves leukopenia from severe neutropenia that resolved with discontinuation of sitagliptin therapy
Other Latest Articles
- Prone Ventilation in Successful Treatment of Severe Leptospirosis with Alveolar Hemorrhage Syndrome and ARDS
- Screening of Genes That May be Associated with Gastric Cancer Using Bioinformatics and Artificial Intelligence Methods and Interpretation of IndividualBased Results
- Satisfaction with Warfarin Therapy and It’s Relation with International Normalized Ratio Monitoring
- A Review of Security in Adaptive Video Streaming
- Korean Students in the Philippines: Their Perceptions of Native and Non-Native English-Speaking Teachers in ELT Classroom
Last modified: 2024-01-09 16:07:55